Recently, Pegcetacoplan intravitreal injection (complement C3-cleavage inhibitor) was approved by the FDA in 2023 for a reduction in the further progression of advanced-stage non-exudative AMD, which is the only treatment available to date. This evidence concerns the gene C3 and age-related macular degeneration.